<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> has been shown to protect against <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>-reperfusion injury </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the effects of <z:chebi fb="1" ids="50694">minocycline</z:chebi> on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>Anesthetized male rats were once treated with <z:chebi fb="1" ids="50694">minocycline</z:chebi> (45mg/kg, i.p.) 1h before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in the absence and/or presence of 2-(4-morpholinyl)-8-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-1(4H)-<z:chebi fb="0" ids="22727">benzopyran</z:chebi>-4-one <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> (LY294002, 0.3mg/kg, i.v., a PI3K inhibitor) and 5-hydroxydecanoic acid [5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, 10mg/kg, i.v., a specific inhibitor of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ATP-sensitive <z:chebi fb="120" ids="26216">potassium</z:chebi> (K(ATP)) channels] which were once injected 10min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and then subjected to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> for 30min </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0004308'>Ventricular arrhythmias</z:hpo> were assessed </plain></SENT>
<SENT sid="4" pm="."><plain>L-type Ca(2+) current was measured by the patch-clamp technique </plain></SENT>
<SENT sid="5" pm="."><plain>During the 30-minute <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, <z:chebi fb="1" ids="50694">minocycline</z:chebi> significantly reduced the incidence of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) (P&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>The duration of VT+<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, the number of VT+<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> episodes and the severity of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> were <z:hpo ids='HP_0000001'>all</z:hpo> significantly reduced by <z:chebi fb="1" ids="50694">minocycline</z:chebi> compared to those in <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> group (P&lt;0.05 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of LY294002 or 5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> abolished the protective effects of <z:chebi fb="1" ids="50694">minocycline</z:chebi> on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> incidence, the duration of VT+<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, the number of VT+<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> episodes and the severity of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (P&lt;0.05 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, <z:chebi fb="1" ids="50694">minocycline</z:chebi> inhibited L-type Ca(2+) currents of <z:mpath ids='MPATH_458'>normal</z:mpath> myocardial cell membrane in a dose-dependent manner </plain></SENT>
<SENT sid="9" pm="."><plain>This study suggested that <z:chebi fb="1" ids="50694">minocycline</z:chebi> could attenuate <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in rats in which PI3K/Akt signaling pathway, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> K(ATP) channels and L-type Ca(2+) channels may be involved </plain></SENT>
</text></document>